Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.49 |
| ▸ | MAN2A1 | Q16706 | 3/20 | 0.46 |
| ▸ | MAN1B1 | Q9UKM7 | 3/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | MAN2B1 | O00754 | 3/20 | 0.44 |
| ▸ | GPR88 | Q9GZN0 | 3/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8549011 | 1.00 | RIPK1 (0.49) | RIPK1MAN2A1MAN1B1SIGMAR1MAN2B1 | |
| SCHEMBL8549178 | 1.00 | RIPK1 (0.49) | RIPK1MAN2A1MAN1B1SIGMAR1MAN2B1 | |
| SCHEMBL25590552 | 0.86 | NAAA (0.51) | RIPK1GPR88ALDH1A1POLBMAPT | |
| SCHEMBL19954198 | 0.85 | TRPA1 (0.43) | RIPK1SIGMAR1MTORRAB9AGRM7 | |
| SCHEMBL258306 | 0.84 | MAN2A1 (0.49) | RIPK1MAN2A1MAN1B1MAN2B1GPR88 | |
| SCHEMBL13520315 | 0.84 | RIPK1 (0.51) | RIPK1MAN2A1MAN1B1SIGMAR1MAN2B1 | |
| SCHEMBL13911223 | 0.84 | SIGMAR1 (0.48) | SIGMAR1EPHX2MTORRAB9AGRM7 | |
| SCHEMBL3165645 | 0.84 | RIPK1 (0.51) | RIPK1MAN2A1MAN1B1SIGMAR1MAN2B1 | |
| SCHEMBL10282547 | 0.84 | RIPK1 (0.51) | RIPK1MAN2A1MAN1B1SIGMAR1MAN2B1 | |
| SCHEMBL12609158 | 0.84 | HTT (0.46) | RIPK1MAN2A1MAN1B1MAN2B1GPR88 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4183782-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DI ONE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2023-05-24 | — | — | EP | disclosed |
| EP-3904354-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | Perha Pharmaceuticals (FR) | 2021-11-03 | — | — | EP | disclosed |
| US-10647701-B2 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2020-05-12 | — | — | US | disclosed |
| US-5821255-A | REGULATING THE SECRETION OF CORTICOTROPIN, BETA-ENDORPHIN OR PEPTIDES DERIVED FROM PROOPIOMELANOCORTIN | SANOFI (FR) | 1998-10-13 | — | — | US | disclosed |
| EP-0659747-B1 | Branched aminothiazole derivatives process for their preparation and pharmaceutical compositions containing them | SANOFI SA (FR) | 1998-04-01 | — | — | EP | disclosed |
| US-5602132-A | USEFUL IN TREATMENT OF PATHOLOGIES INVOLVING CORTICOTROPIN RELEASING FACTOR | SANOFI (FR) | 1997-02-11 | — | — | US | disclosed |
| CN-1127252-A | Branched-amino-sbustituted thiazoles, processes for their preparation and the pharmaceutical compositions which contain them | SANOFI SA (FR) | 1996-07-24 | — | — | CN | disclosed |
| EP-0659747-A1 | Branched aminothiazole derivatives process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1995-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647701-B2 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | XDH, H1-0, RXFP1 | RIPK1 3092/4885MAN2A1 1546/4885MAN1B1 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.